Celgene Backs into Biotech
Executive Summary
A marketed product, a second in registration, and $300 million cash enabled Celgene to acquire a biotech capability and expand beyond its roots as a chiral chemistry company. But it took 15 years to get there. Formed as a bioremediation and chiral chemistry company in 1986, it struggled with those businesses. However, its chemical mentality led to in-licensing rights to thalidomide, which subsequently demonstrated activity in cancer. It reached profitability last year on sales of that drug, and with a chiral form of Ritalin pending approval, it finally had the resources to backfill a biology capability. Its purchase of Signal Pharmaceuticals gives it that and is its solution to the late-stage model problem of how to move beyond initial products and leverage a commercial infrastructure.
You may also be interested in...
Millennium: The Risks of Forward Integration
Millennium Pharmaceuticals has been spending much of the new century building a development organization. Much of this nuts-and-bolts endeavor came out of its acquisition of Cor Therapeutics in 2001, a transforming transaction that has delivered only mixed results, and has now put the company on a hard-to-steer and equally hard-to-alter course.
'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Need a specific report? 1000+ reports available
Buy Reports